Regentis Biomaterials (RGNT) Cash & Equivalents (2024 - 2025)
Regentis Biomaterials (RGNT) posted quarterly Cash & Equivalents of $7.4 million for Q4 2025, up 3121.83% year-over-year from $229000.0 in Q4 2024, and up 3121.83% quarter-over-quarter from $229000.0 in Q4 2024.
Regentis Biomaterials (RGNT) Cash & Equivalents (2024 - 2025) Analysis & Trends
Regentis Biomaterials (RGNT) has reported Cash & Equivalents for 2 consecutive years, with $7.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents rose 3121.83% year-over-year to $7.4 million; the TTM figure through Dec 2025 stood at $7.4 million (up 3121.83% YoY), while the FY2025 annual figure was $7.4 million, up 3121.83% from the prior year.
- Cash & Equivalents advanced to $7.4 million in Q4 2025 per RGNT's latest filing, from $229000.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $7.4 million in Q4 2025 and bottomed at $229000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 2.76 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 708.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 1.36 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 1.47 Bn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 2.33 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 435.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 403.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 138.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 2.15 Bn |
| 10 | Regentis Biomaterials | 1.21 Mn | -6.17 Mn | - | 7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 229,000.00 |